Thermo Fisher Scientific (TMO) said Thursday that it has signed a strategic collaboration agreement with Precision Health Research, Singapore, to advance the PRECISE-SG100K study.
Financial terms were not disclosed.
The company said the study is monitoring long-term health outcomes related to environmental, lifestyle, and genetic factors associated with diseases such as diabetes, hypertension, and cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments